Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common MS drug help stroke patients? new trial begins

NCT ID NCT07275515

Recruiting now Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether Diroximel Fumarate, a drug already used for multiple sclerosis, can reduce harmful brain swelling that often occurs after a hemorrhagic stroke. The swelling, called perihematomal edema, can worsen recovery. The trial will enroll 192 adults who have had a stroke, giving them either the drug or a placebo for 21 days. Researchers will measure brain swelling on CT scans and check functional outcomes after 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Diroximel Fumarate
What this could lead to
If it works, this could point toward a new treatment to reduce brain swelling and improve recovery after a hemorrhagic stroke.
What could go wrong
This is an early Phase 2 trial with only 192 people, so results may not confirm benefit. The drug is repurposed from multiple sclerosis, and its effect on stroke-related swelling is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPONTANEOUS INTRACEREBRAL HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STROKE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Lille

    RECRUITING

    Lille, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.